Imaging glutamate in schizophrenia: review of findings and implications for drug discovery
暂无分享,去创建一个
M Slifstein | J. Lieberman | D. Javitt | L. Kegeles | A. Abi-Dargham | M. Slifstein | R. Girgis | J. Kantrowitz | D C Javitt | J A Lieberman | Joshua T. Kantrowitz | A Abi-Dargham | L S Kegeles | R R Girgis | E M P Poels | J T Kantrowitz | E. M. Poels | Eline M. P. Poels
[1] J. Lauriello,et al. 1H-MRS at 4 Tesla in minimally treated early schizophrenia , 2010, Molecular Psychiatry.
[2] Mark S. Bolding,et al. Multimodal analysis of the hippocampus in schizophrenia using proton magnetic resonance spectroscopy and functional magnetic resonance imaging , 2012, Schizophrenia Research.
[3] U. Campbell,et al. Metabotropic glutamate receptors: potential drug targets for the treatment of schizophrenia. , 2002, Current drug targets. CNS and neurological disorders.
[4] A. Malhotra,et al. Effects of NMDA antagonism on striatal dopamine release in healthy subjects: Application of a novel PET approach , 1998, Synapse.
[5] R. Conley,et al. First-Episode Schizophrenia , 2012, Drugs.
[6] Sandra M. Sanabria-Bohórquez,et al. The synthesis and preclinical evaluation in rhesus monkey of [18F]MK‐6577 and [11C]CMPyPB glycine transporter 1 positron emission tomography radiotracers , 2011, Synapse.
[7] Jenna M. Sullivan,et al. Kinetic Analysis of the Metabotropic Glutamate Subtype 5 Tracer [18F]FPEB in Bolus and Bolus-Plus-Constant-Infusion Studies in Humans , 2013, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[8] P Boesiger,et al. Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo , 2000, The European journal of neuroscience.
[9] T. Yen,et al. Synthesis and evaluation of [18F]Fluorobutyl ethacrynic amide: a potential PET tracer for studying glutathione transferase. , 2012, Bioorganic & medicinal chemistry letters.
[10] Christer Halldin,et al. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: A double-blind PET study of schizophrenic patients , 1993, Biological Psychiatry.
[11] Thomas G Schulze,et al. Decreased frontal lobe ratio of N-acetyl aspartate to choline in familial schizophrenia: a proton magnetic resonance spectroscopy study , 2000, Neuroscience Letters.
[12] Albert D. Windhorst,et al. Radiosynthesis and preclinical evaluation of ( 11 C) , 2013 .
[13] Takayuki Obata,et al. Negative Correlation between Brain Glutathione Level and Negative Symptoms in Schizophrenia: A 3T 1H-MRS Study , 2008, PloS one.
[14] Paul Allen,et al. Altered Medial Temporal Activation Related to Local Glutamate Levels in Subjects with Prodromal Signs of Psychosis , 2011, Biological Psychiatry.
[15] P. Williamson,et al. An in vivo proton magnetic resonance spectroscopy study of schizophrenia patients. , 1996, Schizophrenia bulletin.
[16] F. Liu,et al. ADX47273 [S-(4-Fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piperidin-1-yl}-methanone]: A Novel Metabotropic Glutamate Receptor 5-Selective Positive Allosteric Modulator with Preclinical Antipsychotic-Like and Procognitive Activities , 2008, Journal of Pharmacology and Experimental Therapeutics.
[17] M. Geyer,et al. The mGluR5 antagonist MPEP, but not the mGluR2/3 agonist LY314582, augments PCP effects on prepulse inhibition and locomotor activity , 2002, Neuropharmacology.
[18] A. Kulak. N-ACETYLCYSTEINE NORMALIZES NEUROCHEMICAL CHANGES IN THE GLUTATHIONE-DEFICIENT SCHIZOPHRENIA MOUSE MODEL DURING DEVELOPMENT , 2012, Schizophrenia Research.
[19] Volker Arolt,et al. Learning potential on the WCST in schizophrenia is related to the neuronal integrity of the anterior cingulate cortex as measured by proton magnetic resonance spectroscopy , 2008, Schizophrenia Research.
[20] G. Barker,et al. Ketamine effects on brain GABA and glutamate levels with 1H-MRS: relationship to ketamine-induced psychopathology , 2012, Molecular Psychiatry.
[21] K. Uğurbil,et al. Validation of glutathione quantitation from STEAM spectra against edited 1H NMR spectroscopy at 4T: application to schizophrenia , 2005, Magnetic Resonance Materials in Physics, Biology and Medicine.
[22] D. Javitt,et al. N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: The final common pathway on the road to schizophrenia? , 2010, Brain Research Bulletin.
[23] M. Cuénod,et al. N-Acetyl Cysteine as a Glutathione Precursor for Schizophrenia—A Double-Blind, Randomized, Placebo-Controlled Trial , 2008, Biological Psychiatry.
[24] C. Tamminga,et al. Effects of Ketamine in Normal and Schizophrenic Volunteers , 2001, Neuropsychopharmacology.
[25] D. Javitt,et al. Recent advances in the phencyclidine model of schizophrenia. , 1991, The American journal of psychiatry.
[26] H. Tanila,et al. Cortical glutamate–dopamine interaction and ketamine-induced psychotic symptoms in man , 2005, Psychopharmacology.
[27] A. Aliaga,et al. Test‐retest stability of cerebral mGluR5 quantification using [11C]ABP688 and positron emission tomography in rats , 2012, Synapse.
[28] A. Kersting,et al. Evidence for glutamatergic neuronal dysfunction in the prefrontal cortex in chronic but not in first-episode patients with schizophrenia: a proton magnetic resonance spectroscopy study , 2005, Schizophrenia Research.
[29] P. Boesiger,et al. Improved selectivity of double quantum coherence filtering for the detection of glutathione in the human brain in vivo , 2001, Magnetic resonance in medicine.
[30] 田吉 伸哉,et al. Metabolite changes and gender differences in schizophrenia using 3-Tesla proton magnetic resonance spectroscopy (1H-MRS) , 2009 .
[31] Delbert Robinson,et al. An expert panel review of clinical challenges in psychiatry , 2013 .
[32] J. Lauriello,et al. Glutamate as a Marker of Cognitive Function in Schizophrenia: A Proton Spectroscopic Imaging Study at 4 Tesla , 2011, Biological Psychiatry.
[33] Dost Öngür,et al. Abnormal Glutamatergic Neurotransmission and Neuronal-Glial Interactions in Acute Mania , 2008, Biological Psychiatry.
[34] J. Hietala,et al. Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients , 1995, The Lancet.
[35] A. Malhotra,et al. Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia. , 1999, The American journal of psychiatry.
[36] M. Cuénod,et al. Synaptic plasticity impairment and hypofunction of NMDA receptors induced by glutathione deficit: Relevance to schizophrenia , 2006, Neuroscience.
[37] Mark F Bear,et al. Translating Glutamate: From Pathophysiology to Treatment , 2011, Science Translational Medicine.
[38] G. Rosenbaum,et al. Model psychoses and schizophrenia. , 1962, The American journal of psychiatry.
[39] M. Ehlers. Synapse structure: Glutamate receptors connected by the shanks , 1999, Current Biology.
[40] J. Krystal,et al. First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients , 2006, Molecular Psychiatry.
[41] Anil K Malhotra,et al. Ketamine-Induced Exacerbation of Psychotic Symptoms and Cognitive Impairment in Neuroleptic-Free Schizophrenics , 1997, Neuropsychopharmacology.
[42] Dean P. Jones,et al. New double quantum coherence filter for localized detection of glutathione in vivo , 2006, Magnetic resonance in medicine.
[43] R. Yoshimura,et al. Six-month treatment with atypical antipsychotic drugs decreased frontal-lobe levels of glutamate plus glutamine in early-stage first-episode schizophrenia , 2012, Neuropsychiatric disease and treatment.
[44] M. Ota,et al. Glutamatergic changes in the cerebral white matter associated with schizophrenic exacerbation , 2012, Acta psychiatrica Scandinavica.
[45] D Hell,et al. Effects of (S)-ketamine on striatal dopamine: a [11C]raclopride PET study of a model psychosis in humans. , 2000, Journal of psychiatric research.
[46] Philip K. McGuire,et al. Glutamate Dysfunction in People with Prodromal Symptoms of Psychosis: Relationship to Gray Matter Volume , 2009, Biological Psychiatry.
[47] Christine DeLorenzo,et al. In vivo positron emission tomography imaging with [11C]ABP688: binding variability and specificity for the metabotropic glutamate receptor subtype 5 in baboons , 2011, European Journal of Nuclear Medicine and Molecular Imaging.
[48] D. Weinberger. Implications of normal brain development for the pathogenesis of schizophrenia. , 1987, Archives of general psychiatry.
[49] S. Kapur,et al. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. , 2000, The American journal of psychiatry.
[50] B. Kinon,et al. A Multicenter, Inpatient, Phase 2, Double-Blind, Placebo-Controlled Dose-Ranging Study of LY2140023 Monohydrate in Patients With DSM-IV Schizophrenia , 2011, Journal of clinical psychopharmacology.
[51] D. Cyril D’Souza,et al. Potential Psychiatric Applications of Metabotropic Glutamate Receptor Agonists and Antagonists , 2010, CNS drugs.
[52] E. Abercrombie,et al. Effects of MK-801 on spontaneous and amphetamine-stimulated dopamine release in striatum measured with in vivo microdialysis in awake rats , 1996, Brain Research Bulletin.
[53] R. V. Van Heertum,et al. NMDA antagonist effects on striatal dopamine release: Positron emission tomography studies in humans , 2002, Synapse.
[54] Christine DeLorenzo,et al. in vivo Variation in Metabotropic Glutamate Receptor Subtype 5 Binding Using Positron Emission Tomography and [11C]ABP688 , 2011, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[55] R. V. Van Heertum,et al. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[56] Michael Berk,et al. Medial temporal lobe glutathione concentration in first episode psychosis: A 1H-MRS investigation , 2009, Neurobiology of Disease.
[57] A. Lawrence,et al. Presynaptic dopaminergic dysfunction in schizophrenia: a positron emission tomographic [18F]fluorodopa study. , 2004, Archives of general psychiatry.
[58] R. P. Maguire,et al. Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[59] B. Choe,et al. Observation of metabolic changes in chronic schizophrenia after neuroleptic treatment by in vivo hydrogen magnetic resonance spectroscopy. , 1996, Investigative radiology.
[60] Michael Berk,et al. N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action. , 2011, Journal of psychiatry & neuroscience : JPN.
[61] J. Krystal,et al. Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. , 1998, The American journal of psychiatry.
[62] M. Iyo,et al. Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET , 1997, Nature.
[63] M. Geyer,et al. Effect of antipsychotic treatment on the prepulse inhibition deficit of mGluR5 knockout mice , 2004, Psychopharmacology.
[64] A. Egerton,et al. Anterior Cingulate Glutamate Levels Related to Clinical Status Following Treatment in First-Episode Schizophrenia , 2012, Neuropsychopharmacology.
[65] P. Conn,et al. Metabotropic Glutamate Subtype 5 Receptors Modulate Locomotor Activity and Sensorimotor Gating in Rodents , 2003, Journal of Pharmacology and Experimental Therapeutics.
[66] G. Birk,et al. The Selective mGlu5 Receptor Antagonist MTEP, Similar to NMDA Receptor Antagonists, Induces Social Isolation in Rats , 2007, Neuropsychopharmacology.
[67] J. Krystal,et al. Impact of Schizophrenia and Chronic Antipsychotic Treatment on [123I]CNS-1261 Binding to N-Methyl-D-Aspartate Receptors In Vivo , 2005, Biological Psychiatry.
[68] G. Sedvall,et al. PET study of D(1) dopamine receptor binding in neuroleptic-naive patients with schizophrenia. , 2002, The American journal of psychiatry.
[69] J. Lieberman,et al. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs , 2005, Molecular Psychiatry.
[70] J. Walecki,et al. The effect of risperidone on metabolite measures in the frontal lobe, temporal lobe, and thalamus in schizophrenic patients. A proton magnetic resonance spectroscopy (1H MRS). , 2005, Pharmacopsychiatry.
[71] K. Davis,et al. Dopamine in schizophrenia: a review and reconceptualization. , 1991, The American journal of psychiatry.
[72] Biodistribution and Radiation Dosimetry of the Glycine Transporter-1 Ligand 11C-GSK931145 Determined from Primate and Human Whole-Body PET , 2011, Molecular Imaging and Biology.
[73] D. Javitt,et al. Modulation of Striatal Dopamine Release by Glycine Transport Inhibitors , 2005, Neuropsychopharmacology.
[74] A. Lahti,et al. Regional Decoupling of N-acetyl-aspartate and Glutamate in Schizophrenia , 2012, Neuropsychopharmacology.
[75] Ravi S. Menon,et al. Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers. , 2002, The American journal of psychiatry.
[76] M Laruelle,et al. Alterations of benzodiazepine receptors in type II alcoholic subjects measured with SPECT and [123I]iomazenil. , 1998, The American journal of psychiatry.
[77] S. Miyamoto,et al. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents , 2012, Molecular Psychiatry.
[78] Alan N. Francis,et al. White Matter Alterations in Deficit Schizophrenia , 2008, Neuropsychopharmacology.
[79] A. Kersting,et al. Cognitive Impairment and in Vivo Metabolites in First-episode Neuroleptic-naive and Chronic Medicated Schizophrenic Patients: a Proton Magnetic Resonance Spectroscopy Study , 2006 .
[80] P. Siddarth,et al. Proton magnetic resonance spectroscopy and thought disorder in childhood schizophrenia , 2011, Schizophrenia Research.
[81] J. Roder,et al. Mice Lacking Metabotropic Glutamate Receptor 5 Show Impaired Learning and Reduced CA1 Long-Term Potentiation (LTP) But Normal CA3 LTP , 1997, The Journal of Neuroscience.
[82] Robert Bartha,et al. A short echo proton magnetic resonance spectroscopy study of the left mesial-temporal lobe in first-onset schizophrenic patients , 1999, Biological Psychiatry.
[83] N. Rüsch,et al. Frontolimbic glutamate alterations in first episode schizophrenia: Evidence from a magnetic resonance spectroscopy study , 2008, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.
[84] M. Ercan,et al. Detection of head and neck cancer with 99Tcm glutathione: a correlative study with tissue glutathione and glutathione , 2001, Nuclear medicine communications.
[85] P. Pouwels,et al. Proton magnetic resonance spectroscopy in 22q11 deletion syndrome : Evidence for glutamate and myo-Inositol dysfunction , 2010 .
[86] Michael Berk,et al. Glutathione depletion in the brain disrupts short-term spatial memory in the Y-maze in rats and mice , 2009, Behavioural Brain Research.
[87] Paolo Fusar-Poli,et al. THALAMIC GLUTAMATE LEVELS AS A PREDICTOR OF CORTICAL RESPONSE DURING EXECUTIVE FUNCTIONING IN SUBJECTS AT HIGH RISK FOR PSYCHOSIS , 2012, Schizophrenia Research.
[88] A. Malhotra,et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[89] J. Levitt,et al. Preliminary study of frontal lobe 1H MR spectroscopy in childhood‐onset schizophrenia , 1998, Journal of magnetic resonance imaging : JMRI.
[90] R. Narendran,et al. Increased prefrontal cortical D1 receptors in drug naïve patients with schizophrenia: a PET study with [11C]NNC112 , 2012, Journal of psychopharmacology.
[91] V. Haroutunian,et al. Contribution of Cystine–Glutamate Antiporters to the Psychotomimetic Effects of Phencyclidine , 2008, Neuropsychopharmacology.
[92] A. Graff-Guerrero,et al. Glutamate levels in the associative striatum before and after 4 weeks of antipsychotic treatment in first-episode psychosis: a longitudinal proton magnetic resonance spectroscopy study. , 2013, JAMA psychiatry.
[93] J. Lauriello,et al. Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4-T proton MRS study. , 2005, The American journal of psychiatry.
[94] J. Krystal,et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. , 1994, Archives of general psychiatry.
[95] Vidhi Singh,et al. Meta-Analysis of the Efficacy of Adjunctive NMDA Receptor Modulators in Chronic Schizophrenia , 2011, CNS drugs.
[96] Francesco Ferraguti,et al. Metabotropic glutamate receptors , 2006, Cell and Tissue Research.
[97] J. Uslaner,et al. Dose-dependent effect of CDPPB, the mGluR5 positive allosteric modulator, on recognition memory is associated with GluR1 and CREB phosphorylation in the prefrontal cortex and hippocampus , 2009, Neuropharmacology.
[98] Alan C. Evans,et al. Elevated dopa decarboxylase activity in living brain of patients with psychosis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[99] Anil Kumar,et al. Characterization of [11C]RO5013853, a novel PET tracer for the glycine transporter type 1 (GlyT1) in humans , 2013, NeuroImage.
[100] J. Lieberman,et al. Provocative tests with psychostimulant drugs in schizophrenia , 2004, Psychopharmacology.
[101] M. Foster Olive,et al. mGluR5 positive allosteric modulators facilitate both hippocampal LTP and LTD and enhance spatial learning , 2009, Neuropsychopharmacology.
[102] P. Worley,et al. Coupling of mGluR/Homer and PSD-95 Complexes by the Shank Family of Postsynaptic Density Proteins , 1999, Neuron.
[103] Mark Slifstein,et al. Elevated prefrontal cortex γ-aminobutyric acid and glutamate-glutamine levels in schizophrenia measured in vivo with proton magnetic resonance spectroscopy. , 2012, Archives of general psychiatry.
[104] N. Volkow,et al. Glutamate Modulation of Dopamine Measured in Vivo with Positron Emission Tomography (PET) and 11C-Raclopride in Normal Human Subjects , 1998, Neuropsychopharmacology.
[105] M. Laruelle,et al. Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia , 2000, Biological Psychiatry.
[106] D. Javitt,et al. Glutamate as a therapeutic target in psychiatric disorders , 2004, Molecular Psychiatry.
[107] Martin Büchert,et al. Increased Prefrontal and Hippocampal Glutamate Concentration in Schizophrenia: Evidence from a Magnetic Resonance Spectroscopy Study , 2005, Biological Psychiatry.
[108] J. Walecki,et al. Proton Magnetic Resonance Spectroscopy Study of Brain Metabolite Changes after Antipsychotic Treatment , 2011, Pharmacopsychiatry.
[109] P. Cowen,et al. Lack of effect of ketamine on cortical glutamate and glutamine in healthy volunteers: a proton magnetic resonance spectroscopy study , 2012, Journal of psychopharmacology.
[110] G Bernardi,et al. Metabotropic glutamate receptor 5 mediates the potentiation of N-methyl-D-aspartate responses in medium spiny striatal neurons , 2001, Neuroscience.
[111] L. Herzenberg,et al. N-Acetylcysteine--a safe antidote for cysteine/glutathione deficiency. , 2007, Current opinion in pharmacology.
[112] J. Kwon,et al. Proton magnetic resonance spectroscopy in subjects with high genetic risk of schizophrenia: Investigation of anterior cingulate, dorsolateral prefrontal cortex and thalamus , 2009, Schizophrenia Research.
[113] A. Graff-Guerrero,et al. Striatal glutamate and the conversion to psychosis: a prospective 1H-MRS imaging study. , 2013, The international journal of neuropsychopharmacology.
[114] A. Graff-Guerrero,et al. Higher Levels of Glutamate in the Associative-Striatum of Subjects with Prodromal Symptoms of Schizophrenia and Patients with First-Episode Psychosis , 2011, Neuropsychopharmacology.
[115] J. Hirvonen,et al. Ketamine does not decrease striatal dopamine D2 receptor binding in man , 2002, Psychopharmacology.
[116] Ravi S. Menon,et al. Comparative study of proton and phosphorus magnetic resonance spectroscopy in schizophrenia at 4 Tesla , 2004, Psychiatry Research: Neuroimaging.
[117] J. Walecki,et al. Duration of untreated psychosis and proton magnetic resonance spectroscopy (1H-MRS) findings in first-episode schizophrenia. , 2009, Medical science monitor : international medical journal of experimental and clinical research.
[118] James Robert Brašić,et al. 18F-FPEB, a PET Radiopharmaceutical for Quantifying Metabotropic Glutamate 5 Receptors: A First-in-Human Study of Radiochemical Safety, Biokinetics, and Radiation Dosimetry , 2013, The Journal of Nuclear Medicine.
[119] R. V. Van Heertum,et al. Prefrontal Dopamine D1 Receptors and Working Memory in Schizophrenia , 2002, The Journal of Neuroscience.
[120] Ravi S. Menon,et al. Longitudinal grey-matter and glutamatergic losses in first-episode schizophrenia , 2007, British Journal of Psychiatry.
[121] Dennis Velakoulis,et al. Evidence for neuronal dysfunction in the anterior cingulate of patients with schizophrenia: A proton magnetic resonance spectroscopy study at 3 T , 2007, Schizophrenia Research.
[122] Gregor Hasler,et al. Reduced metabotropic glutamate receptor 5 density in major depression determined by [(11)C]ABP688 PET and postmortem study. , 2011, The American journal of psychiatry.
[123] A. Abi-Dargham,et al. Imaging Changes in Glutamate Transmission In Vivo with the Metabotropic Glutamate Receptor 5 Tracer [11C] ABP688 and N-Acetylcysteine Challenge , 2011, Biological Psychiatry.
[124] P. Worley,et al. Shank, a Novel Family of Postsynaptic Density Proteins that Binds to the NMDA Receptor/PSD-95/GKAP Complex and Cortactin , 1999, Neuron.
[125] P. Calabresi,et al. Cell-type specificity of mGluR activation in striatal neuronal subtypes , 2000, Amino Acids.
[126] James Robert Brašić,et al. Glycine Transporter Type 1 Occupancy by Bitopertin: a Positron Emission Tomography Study in Healthy Volunteers , 2013, Neuropsychopharmacology.
[127] Mark Slifstein,et al. Translational characterization of [11C]GSK931145, a PET ligand for the glycine transporter type 1 , 2011, Synapse.
[128] R W Neufeld,et al. Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy. , 1997, Archives of general psychiatry.
[129] K. Morgan. Radiation dosimetry. , 1981, Science.
[130] Mark Slifstein,et al. Altered prefrontal dopaminergic function in chronic recreational ketamine users. , 2005, The American journal of psychiatry.
[131] R. Vandenberg,et al. Glycine transport inhibitors for the treatment of pain. , 2014, Trends in pharmacological sciences.
[132] B. Faragher,et al. Duration of untreated psychosis in first episode schizophrenia , 1998, Schizophrenia Research.
[133] H. Monyer,et al. NMDA receptor channels: Subunit-specific potentiation by reducing agents , 1994, Neuron.
[134] N. Rüsch,et al. Neurochemical and structural correlates of executive dysfunction in schizophrenia , 2008, Schizophrenia Research.
[135] M. Keshavan,et al. Striatal metabolic alterations in non-psychotic adolescent offspring at risk for schizophrenia: A 1H spectroscopy study , 2009, Schizophrenia Research.
[136] Linda Chang,et al. Brain Metabolite Abnormalities in the White Matter of Elderly Schizophrenic Subjects: Implication for Glial Dysfunction , 2007, Biological Psychiatry.
[137] A. Buck,et al. Increased Metabotropic Glutamate Receptor Subtype 5 Availability in Human Brain After One Night Without Sleep , 2013, Biological Psychiatry.
[138] Alexander Alanine,et al. Selective GlyT1 inhibitors: discovery of [4-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl][5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methylethoxy)phenyl]methanone (RG1678), a promising novel medicine to treat schizophrenia. , 2010, Journal of medicinal chemistry.
[139] Robert C. Knowlton,et al. Assessments of Function and Biochemistry of the Anterior Cingulate Cortex in Schizophrenia , 2010, Biological Psychiatry.
[140] Ravi S. Menon,et al. Grey matter and social functioning correlates of glutamatergic metabolite loss in schizophrenia , 2011, British Journal of Psychiatry.
[141] W. Almaguer-Melian,et al. Behavioral and biochemical effects of glutathione depletion in the rat brain , 2001, Brain Research Bulletin.
[142] J. Krystal,et al. Relationship between ketamine-induced psychotic symptoms and NMDA receptor occupancy—a [123I]CNS-1261 SPET study , 2008, Psychopharmacology.
[143] J. Krystal,et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. , 1996, Proceedings of the National Academy of Sciences of the United States of America.